Dextemp tablets are used:
For symptomatic treatment:
pain and inflammation in osteoarthritis/arthritis; menstrual pain (primary dysmenorrhea); mild to moderate pain such as musculoskeletal pain, headache or toothache, painful swelling and inflammation after injury.
For short-term symptomatic treatment:
rheumatoid arthritis, if other, longer-term therapies (main therapy: antirheumatic drugs) are not considered.
Composition
Active ingredient: dexibuprofen.
1 tablet contains 200 mg or 400 mg of dexibuprofen.
Excipients: microcrystalline cellulose, carmellose calcium, colloidal anhydrous silicon dioxide, hypromellose, talc.
Contraindication
Hypersensitivity to dexibuprofen, other NSAIDs or to other components of the drug; use in patients in whom substances with a similar mechanism of action, such as acetylsalicylic acid and other NSAIDs, cause attacks of bronchial asthma, bronchospasm, acute rhinitis or lead to the development of nasal polyps, urticaria or angioedema; history of bleeding or perforation in the digestive tract associated with the use of NSAIDs; active phase of peptic ulcer disease/bleeding in the digestive tract, history of peptic ulcer disease/bleeding in the digestive tract (at least two confirmed facts of ulcer or bleeding); Crohn's disease or nonspecific ulcerative colitis in the active phase; cerebrovascular bleeding or other bleeding in the active phase; disorders of blood formation or blood clotting; severe hepatic, renal and cardiac failure; last trimester of pregnancy.
Method of application
The dosage regimen is set by the doctor individually, taking into account the intensity of the pain syndrome.
Adults should usually be prescribed 1–2 tablets (200–400 mg of dexibuprofen) 3 times a day after meals.
The recommended starting dose is 200 mg of dexibuprofen.
The recommended daily dose is 600–900 mg of dexibuprofen, divided into 3 doses.
The highest single dose is 400 mg, the highest daily dose is 1200 mg.
Application features
With prolonged use of dexibuprofen, patients should have regular monitoring of renal, hepatic and hematological functions.
Pregnant women
The use of dexibuprofen should be avoided during the first and second trimesters of pregnancy unless the potential benefit to the patient outweighs the potential risk to the fetus. If used during the first or second trimester of pregnancy, the lowest effective dose should be used for the shortest possible period of time. From the beginning of the 6th month of pregnancy, the use of dexibuprofen is contraindicated.
Children
The drug should not be used in pediatric practice.
Drivers
Provided that the recommendations regarding dosage and duration of treatment are followed, the drug does not affect the reaction speed when driving or using other mechanisms. However, in case of dizziness, increased fatigue, drowsiness, disorientation or visual disturbances, driving or using other mechanisms should be avoided.
Overdose
Abdominal pain, nausea, vomiting, lethargy, drowsiness, headache, nystagmus, tinnitus, ataxia, in rare cases – gastrointestinal bleeding, hypotension, hypothermia, metabolic acidosis, convulsions, renal dysfunction, coma, adult respiratory distress syndrome, transient apnea attacks.
Adverse reactions
General disorders: increased fatigue, increased sweating.
Interaction
Anticoagulants: NSAIDs may enhance the effects of anticoagulants such as warfarin. In case of concomitant use, it is recommended to monitor coagulation processes and, if necessary, adjust the dose of anticoagulants.
Other NSAIDs, including acetylsalicylic acid (at a dose of more than 100 mg/day): concomitant use of other NSAIDs, including selective COX-2 inhibitors, may increase the risk of ulcers and bleeding in the gastrointestinal tract.
Lithium: NSAIDs may increase plasma lithium levels by reducing its renal clearance. In case of concomitant use, frequent monitoring of lithium plasma levels should be performed and, if necessary, a reduction in its dose should be considered.
Methotrexate at doses of 15 mg/week or more: when NSAIDs are used within 24 hours before or after taking methotrexate, the level of the latter in the blood plasma may increase due to a decrease in renal clearance and increase the toxic effect.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Keep out of the reach of children.
Shelf life - 2 years.
